Schedule 13G ownership disclosure

Karyopharm Therapeutics Inc

COMMON STOCK · CUSIP: 48576U205

Event date: 2025-10-31

Filing-level shares
2,304,242
Percent of class
13.8%
  • T. Rowe Price Investment Management, Inc.

    Shares: 2,304,242 · Class: 13.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001897612-25-000507
Form type
SCHEDULE 13G/A
Filer
Karyopharm Therapeutics Inc.
CIK
CIK 1503802
Filed
Nov 07, 2025
Reporting period
Oct 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub